You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A collagen wound dressing augmented with a proteoglycan mimic to enhance chronic

    SBC: Angion Biomedica Corp.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver. Over time it frequently progresses to cirrhosis, an end-stage lethal disease which is the seventh leadingcause of death in the United States and afflicts hundreds of millions of people worldwide. Alcohol intake remains the most important cause of li ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Aldosterone Synthase Inhibitor for CKD

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The renin-angiotensin-aldosterone system (RAAS) plays a critical role in renal physiology. Inhibitors of angiotensin-converting enzyme (ACE) or angiotensin receptor blockers (ARB) are the mainstay in the clinical management of renal disorders such as chronic kidney disease (CKD). These treatments are thought to work in large part by reducing serum and renal ald ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. A Multi-channel Web Platform to Provide Holistic Care to Underserved Consumers

    SBC: Transcendent International, LLC            Topic: NIMHD

    DESCRIPTION provided by applicant Significant obstacles exist in care delivery that prevents meaningful utilization of mental health services by consumers who experience health disparities Specifically individuals facing isolation due to linguistic literacy or cultural bariers often face challenges in procuring mental health care These challenges are in part due to the medical and mental systemsan ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. A multiplex panel for simultaneously profiling toxicant levels and biological res

    SBC: ADARZA BIOSYSTEMS, INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): There is increasing interest in the exposure science field in top-down approaches to studying human environmental exposures (the exposome), where toxicants of interest are profiled within the body through blood and/or other biological samples. Such studies would complement more traditional bottom-up approaches where the environment in which an individual lives ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. An Automated Platform for High-throughput Network Electrophysiology

    SBC: CALISTA THERAPEUTICS INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Calista Therapeutics has discovered a first-in-class, proprietary PDZ1-2 lead drug, AT010, that is being optimized and developed as an inhaled daily therapy for cystic fibrosis (CF). CF is a deadly inherited genetic disorder that disrupts chloride channel function, resulting in the buildup of sticky mucus in patient's lungs and other organs.CF patients hav ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. An Evidence-Based Serious Game Approach for Bullying Prevention

    SBC: National Health Promotion Associates, Inc.            Topic: NICHD

    DESCRIPTION (provided by applicant): Bullying, in its most familiar form, is a serious public health concern. This is especially true among middle-school age children. However, the recent increase in social networking websites coupled with the increased availability of more advanced personal devices with a broader range of social applications has dramatically increased the possible types of bullyi ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. A NEW SYSTEM FOR ULTRASONIC ASSESSMENT OF THE CALCANEUS

    SBC: CYBERLOGIC INC            Topic: NIAMS

    DESCRIPTION (provided by applicant): This Lab to Marketplace SBIR Phase I Phase II Fast Track Application has as its long- term objective to establish ultrasound as a safe, effective, and non-invasive method for assessing fracture risk, an important component in clinical management of osteoporosis. Osteoporosis afflicts over 20 million people in the U.S., and is responsible for more than 275,000 ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. An Open Source Digital Pathology System Supporting Multi-Touch Interaction

    SBC: KITWARE INC            Topic: NIBIB

    DESCRIPTION (provided by applicant): This application addresses Innovations in Biomedical Computational Science and Technology Initiative PAR-09-220. Healthcare is moving towards fully digitized patient records. Surgical pathology represents a challenge inthat high resolution imaging of tissue sections on glass slides produces datasets that are large compared to those of clinical pathology (e.g., ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. A novel, multiparametric cardiac safety assay using human myocytes

    SBC: THERAPYX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Genital tract infection with Neisseria gonorrhoeae (gonorrhea) does not induce a state of specific protective immunity and can be acquired repeatedly. Despite public health measures, the disease persists at an unacceptably high frequency; there is no vaccine against it, and resistance even to the latest generations of antibiotics continues to emerge. New findin ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Thioredoxin Mimetic Prodrug for Prevention of Bronchopulmonary Dysplasia

    SBC: CORSOLUTIONS, LLC            Topic: NIBIB

    DESCRIPTION (provided by applicant): The merging of cell culture and microfluidic technology has resulted in improved in vitro models for toxicity studies, drug development, and biomedical research. The reason for which microfluidic approaches provide a more accurate in vitro model of in vivo effects is because devices can be designed with unique properties to closely mimic the in vivo environment ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government